— Know what they know.
Not Investment Advice

MRVI NASDAQ

Maravai LifeSciences Holdings, Inc.
1W: +14.7% 1M: +8.3% 3M: +25.3% YTD: +142.9% 1Y: +142.2% 3Y: +19.5% 5Y: -79.3%
$8.26
+0.68 (+8.97%)
After Hours: $8.23 (-0.03, -0.30%)
Weekly Expected Move ±11.1%
$6 $7 $7 $8 $9
NASDAQ · Healthcare · Biotechnology · Tech Score Buy · Power 59 · $2.3B mcap · 106M float · 3.02% daily turnover · Short 53% of daily vol
Credit Risk of going bust: higher than 51% of companies Debt: 7.6% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.07 (down 99.1%), Maravai LifeSciences Holdings, Inc. would be worth roughly what it owes.
Total debt $176.7M against a stock market value of $2.15B.
Distance to default 5.01 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $74.1M (short-term plus half of long-term), stock volatility 66.7%; Altman Z'' 0.85. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Balance Sheet Trends

Total Assets
$771M -23.6% ▼
5Y CAGR: -9.5%
Total Liabilities
$398M -7.7% ▼
5Y CAGR: -18.6%
Shareholders Equity
$212M -34.7% ▼
5Y CAGR: +19.1%
Cash & Investments
$217M -32.7% ▼
5Y CAGR: -1.7%
Total Debt
$36M -90.6% ▼
5Y CAGR: -43.0%
Net Debt
-$181M -433.9% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$551M$632M$575M$322M$217M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$551M$632M$575M$322M$217M
Net Receivables$118M$147M$56M$39M$25M
Inventory$52M$43M$51M$50M$40M
Other Current Assets$0$26M$18M$18M$13M
Total Current Assets$740M$848M$700M$429M$296M
Property, Plant & Equip.$95M$117M$223M$217M$1M
Goodwill & Intangibles$270M$500M$547M$355M$281M
Long-Term Investments$0$11M$9M$0$0
Other Non-Current Assets$4M$40M$9M$7M$192M
Total Non-Current Assets$1.2B$1.4B$788M$579M$474M
Total Assets$1.9B$2.3B$1.5B$1.0B$771M
— Liabilities —
Accounts Payable$8M$6M$11M$12M$0
Short-Term Debt$6M$5M$5M$5M$5M
Deferred Revenue$13M$3M$3M$3M$0
Other Current Liabilities$19M$69M$48M$0$39M
Total Current Liabilities$94M$110M$87M$57M$45M
Long-Term Debt$525M$522M$519M$290M$30M
Other Non-Current Liab.$714M$693M$12M$11M$323M
Total Non-Current Liabilities$1.3B$1.3B$610M$374M$353M
Total Liabilities$1.4B$1.4B$698M$431M$398M
— Equity —
Common Stock$3M$3M$3M$3M$3M
Retained Earnings$185M$405M$286M$141M$10M
Accumulated OCI$0$0$0$0$524K
Total Stockholders Equity$315M$545M$417M$325M$212M
Total Liabilities & Equity$1.9B$2.3B$1.5B$1.0B$771M
— Key Metrics —
Total Debt$575M$585M$611M$377M$36M
Net Debt$24M-$47M$36M$54M-$181M
Total Investments$0$11M$9M$0$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms